Pasar al contenido principal

DISEÑOS ANTIVIRICOS BASADOS EN MUTAGENESIS LETAL

BFU2011-23604

•
Nombre agencia financiadora Ministerio de Ciencia e Innovación
Acrónimo agencia financiadora MICINN
Programa Programa Nacional de Proyectos de Investigación Fundamental
Subprograma Subprograma de Proyectos de Investigación Fundamental no Orientada
Convocatoria Proyectos I+D
Año convocatoria 2011
Plan Estatal 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Unidad de gestión Subdirección General de Proyectos de Investigación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Identificador persistente http://dx.doi.org/10.13039/501100004837

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus

  • Soria Benito, María Eugenia|||0000-0002-4719-3351
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Chen, Qian
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Llorens, Meritxell
  • de Ávila, Ana Isabel
  • Beach, Nathan M.
  • Domingo, Esteban
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Buti, Maria|||0000-0002-0732-3078
  • Esteban, Rafael|||0000-0001-5280-392X
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Quer, Josep|||0000-0003-0014-084X
  • Perales Viejo, Celia|||0000-0003-1618-1937
Despite the high sustained virological response rates achieved with current directly-acting antiviral agents (DAAs) against hepatitis C virus (HCV), around 5-10% of treated patients do not respond to current antiviral therapies, and basal resistance to DAAs is increasingly detected among treatment-naïve infected individuals. Identification of amino acid substitutions (including those in minority variants) associated with treatment failure requires analytical designs that take into account the high diversification of HCV in more than 86 subtypes according to the ICTV website (June 2017). The methodology has involved five sequential steps: (i) to design 280 oligonucleotide primers (some including a maximum of three degenerate positions), and of which 120 were tested to amplify NS3, NS5A-, and NS5B-coding regions in a subtype-specific manner, (ii) to define a reference sequence for each subtype, (iii) to perform experimental controls to define a cut-off value for detection of minority amino acids, (iv) to establish bioinformatics' tools to quantify amino acid replacements, and (v) to validate the procedure with patient samples. A robust ultra-deep sequencing procedure to analyze HCV circulating in serum samples from patients infected with virus that belongs to the ten most prevalent subtypes worldwide: 1a, 1b, 2a, 2b, 2c, 2j, 3a, 4d, 4e, 4f has been developed. Oligonucleotide primers are subtype-specific. A cut-off value of 1% mutant frequency has been established for individual mutations and haplotypes. The methodological pipeline described here is adequate to characterize in-depth mutant spectra of HCV populations, and it provides a tool to understand HCV diversification and treatment failures. The pipeline can be periodically extended in the event of HCV diversification into new genotypes or subtypes, and provides a framework applicable to other RNA viral pathogens, with potential to couple detection of drug-resistant mutations with treatment planning. The online version of this article (10.1186/s12879-018-3356-6) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Rare haplotype load as marker for lethal mutagenesis

  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Soria Benito, María Eugenia|||0000-0002-4719-3351
  • Gallego, Isabel
  • Guerrero Murillo, Mercedes|||0000-0002-5556-2460
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Quer, Josep|||0000-0003-0014-084X
  • Perales Viejo, Celia|||0000-0003-1618-1937
  • Domingo, Esteban
RNA viruses replicate with a template-copying fidelity, which lies close to an extinction threshold. Increases of mutation rate by nucleotide analogues can drive viruses towards extinction. This transition is the basis of an antiviral strategy termed lethal mutagenesis. We have introduced a new diversity index, the rare haplotype load (RHL), to describe NS5B (polymerase) mutant spectra of hepatitis C virus (HCV) populations passaged in absence or presence of the mutagenic agents favipiravir or ribavirin. The increase in RHL is more prominent in mutant spectra whose expansions were due to nucleotide analogues than to multiple passages in absence of mutagens. Statistical tests for paired mutagenized versus non-mutagenized samples with 14 diversity indices show that RHL provides consistently the highest standardized effect of mutagenic treatment difference for ribavirin and favipiravir. The results indicate that the enrichment of viral quasispecies in very low frequency minority genomes can serve as a robust marker for lethal mutagenesis. The diagnostic value of RHL from deep sequencing data is relevant to experimental studies on enhanced mutagenesis of viruses, and to pharmacological evaluations of inhibitors suspected to have a mutagenic activity.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir

  • de Ávila, Ana Isabel
  • Gallego, Isabel
  • Soria, Maria Eugenia
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Quer, Josep|||0000-0003-0014-084X
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Rice, Charles M.|||0000-0003-3087-8079
  • Domingo, Esteban
  • Perales Viejo, Celia|||0000-0003-1618-1937
Lethal mutagenesis is an antiviral approach that consists in extinguishing a virus by an excess of mutations acquired during replication in the presence of a mutagen. Here we show that favipiravir (T-705) is a potent mutagenic agent for hepatitis C virus (HCV) during its replication in human hepatoma cells. T-705 leads to an excess of G → A and C → U transitions in the mutant spectrum of preextinction HCV populations. Infectivity decreased significantly in the presence of concentrations of T-705 which are 2- to 8-fold lower than its cytotoxic concentration 50 (CC). Passaging the virus five times in the presence of 400 μM T-705 resulted in virus extinction. Since T-705 has undergone advanced clinical trials for approval for human use, the results open a new approach based on lethal mutagenesis to treat hepatitis C virus infections. If proven effective for HCV in vivo, this new anti-HCV agent may be useful in patient groups that fail current therapeutic regimens.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Ultra-Deep Pyrosequencing (UDPS) Data Treatment to Study Amplicon HCV Minor Variants

  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Esteban Mur, Juan Ignacio|||0000-0001-5085-917X
  • Cubero, María Dolores|||0000-0002-2072-0828
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • Perales Viejo, Celia|||0000-0003-1618-1937
  • Casillas, Rosario|||0000-0002-6758-6734
  • Alvarez-Tejado, Miguel
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Guardia Massó, Jaume
  • Domingo, Esteban
  • Quer, Josep|||0000-0003-0014-084X
We have investigated the reliability and reproducibility of HCV viral quasispecies quantification by ultra-deep pyrosequencing (UDPS) methods. Our study has been divided in two parts. First of all, by UDPS sequencing of clone mixes samples we have established the global noise level of UDPS and fine tuned a data treatment workflow previously optimized for HBV sequence analysis. Secondly, we have studied the reproducibility of the methodology by comparing 5 amplicons from two patient samples on three massive sequencing platforms (FLX+, FLX and Junior) after applying the error filters developed from the clonal/control study. After noise filtering the UDPS results, the three replicates showed the same 12 polymorphic sites above 0.7%, with a mean CV of 4.86%. Two polymorphic sites below 0.6% were identified by two replicates and one replicate respectively. A total of 25, 23 and 26 haplotypes were detected by GS-Junior, GS-FLX and GS-FLX+. The observed CVs for the normalized Shannon entropy (Sn), the mutation frequency (Mf), and the nucleotidic diversity (Pi) were 1.46%, 3.96% and 3.78%. The mean absolute difference in the two patients (5 amplicons each), in the GS-FLX and GS-FLX+, were 1.46%, 3.96% and 3.78% for Sn, Mf and Pi. No false polymorphic site was observed above 0.5%. Our results indicate that UDPS is an optimal alternative to molecular cloning for quantitative study of HCV viral quasispecies populations, both in complexity and composition. We propose an UDPS data treatment workflow for amplicons from the RNA viral quasispecies which, at a sequencing depth of at least 10,000 reads per strand, enables to obtain sequences and frequencies of consensus haplotypes above 0.5% abundance with no erroneous mutations, with high confidence, resistant mutants as minor variants at the level of 1%, with high confidence that variants are not missed, and highly confident measures of quasispecies complexity.